ArticleFrontiers in medicine2021
Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05799755 (Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory Trial
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease.Clinical reviews in allergy & immunology · 2026Review
- Navigating the Challenges of Treating Autoimmune-Inflammatory Myopathy-Related Interstitial Lung Disease With Nintedanib.CHEST pulmonary · 2026Article
- Tolerability and Safety of Nintedanib and Immunosuppression in Autoimmune Inflammatory Myopathy-Associated Progressive Pulmonary Fibrosis.CHEST pulmonary · 2026Article
- Treatment Response and Safety Profile of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease: A Retrospective Observational Study.Mediterranean journal of rheumatology · 2025Article
- Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.Biomedicines · 2025Review
- Article
- Idiopathic inflammatory myopathies related lung disease in adults.The Lancet. Respiratory medicine · 2025Review
- Idiopathic Inflammatory Myopathies-Associated Interstitial Lung Disease in Adults.Tuberculosis and respiratory diseases · 2025Article
- Different faces of anti-melanoma differentiation-associated gene 5 antibody-positive myositis.Reumatologia · 2025Article
- Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.Pharmaceuticals (Basel, Switzerland) · 2024Review
- A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.International journal of molecular sciences · 2024Review
- Roles of TRIM21/Ro52 in connective tissue disease-associated interstitial lung diseases.Frontiers in immunology · 2024Review
- Article
- Biological Therapies in Inflammatory Myopathies.Rambam Maimonides medical journal · 2023Review
- Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience.Diagnostics (Basel, Switzerland) · 2023Article
- An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome.Clinical rheumatology · 2023Observational
- Predictors of progression in idiopathic inflammatory myopathies with interstitial lung disease.Journal of translational internal medicine · 2023Article
- Progressive pulmonary fibrosis in myositis-specific antibody-positive interstitial pneumonia: a retrospective cohort study.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.